The Carlyle Group made a strategic growth investment and will acquire a majority stake in TriNetX, a global health research network focused on clinical research to bring new therapies to market faster.
Terms of the deal were undisclosed.
The $221 billion private equity giant has invested more than $15 billion of equity since inception in healthcare-oriented companies.
“With a deep clinical focus and a highly scalable data strategy, we believe TriNetX is well positioned for continued organic and inorganic growth opportunities,” said Joe Bress, a principal specializing in healthcare at The Carlyle . . .
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators